UK markets close in 6 hours 3 minutes
  • FTSE 100

    7,186.99
    +17.71 (+0.25%)
     
  • FTSE 250

    18,756.54
    +89.76 (+0.48%)
     
  • AIM

    877.43
    +1.21 (+0.14%)
     
  • GBP/EUR

    1.1553
    -0.0058 (-0.50%)
     
  • GBP/USD

    1.2079
    -0.0096 (-0.79%)
     
  • BTC-GBP

    16,163.47
    +304.85 (+1.92%)
     
  • CMC Crypto 200

    420.43
    -11.03 (-2.56%)
     
  • S&P 500

    3,785.38
    -33.45 (-0.88%)
     
  • DOW

    30,775.43
    -253.88 (-0.82%)
     
  • CRUDE OIL

    107.60
    +1.84 (+1.74%)
     
  • GOLD FUTURES

    1,795.70
    -11.60 (-0.64%)
     
  • NIKKEI 225

    25,935.62
    -457.42 (-1.73%)
     
  • HANG SENG

    21,859.79
    -137.10 (-0.62%)
     
  • DAX

    12,829.94
    +46.17 (+0.36%)
     
  • CAC 40

    5,949.11
    +26.25 (+0.44%)
     

Atos, UCL and Arm team up to offer wider cloud computing possibilities for life sciences applications

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Atos International
Atos International

Atos, UCL and Arm team up to offer wider cloud computing possibilities for life sciences applications

Paris, France June 1st, 2022 Atos and UCL today announce having successfully run the virus sequencing tool, Viridian, which is used to detect mutation of the SARS-Cov-2 strain of the coronavirus, using an Arm®-based Ampere® Altra® processor in a cloud native environment with Atos’ integration expertise. This proof of concept (PoC) was coordinated by Atos' Life Sciences Center of Excellence which aims to foster a culture of exploration, discovery and co-creation to harness the power of digital technologies in order to advance precision health and accelerate the discovery and development of drugs.

With data growing exponentially and becoming more difficult to process for life sciences applications, data, scientists rely on high-performance computing and parallel computing to quickly process and analyse massive amounts of data.

The Arm Neoverse™-based platform, the Ampere Altra, is dedicated to cloud native workloads, meaning the simulation and the results can be achieved not only on-premises but directly on the cloud, on any type of HPC platforms and from anywhere.

This will be even easier with the use of Atos’ Nimbix Supercomputing Suite; offering researchers and scientists flexible, scalable, and easy-to-use cloud solutions for compute-intensive workflows.

With more and more laboratories using Arm-based solutions, this successful PoC means that they will now be able to run Viridian on their systems, enabling them to study life science workflows and to detect various mutations in the SARS-CoV-2 genome, in order to ultimately help combat COVID-19.

This work has combined expertise skills from a team of Atos and Arm experts focusing on hardware and software optimizations, together with a scientific team from UCL dedicated to scientific applications for these specific use cases. This collaboration has enabled the optimization of both software and hardware in this co-designing effort to meet the demands of impactful and cutting-edge genomics workflows, which are already deployed in clinical settings.

Emmanuel Le Roux, Group SVP, Global Head of HPC, AI & Quantum at Atos, commented Being the undisputed European leader in HPC is not only about delivering the most systems to European HPC centers in terms of PetaFlops but also about working closely with numerous European research and scientific institutions to empower various crucial data productions and simulations daily. This work, under the umbrella of the Atos Life Sciences Center of Excellence, demonstrates that collaboration between academia and industry through the power of supercomputing is creating new avenues for scientific breakthroughs. Today, we have once again shown the importance of hybrid computing to foster innovation and provide scientists with tangible life sciences applications.

Alex Wade, Research Associate at UCL, said: “This codesign effort between Arm, Atos and UCL has allowed for the optimization of both new Arm hardware and cutting-edge genomics software, fortifying both for real world life science applications. Collaborating with industry partners has demonstrated a key idea for the future of HPC applications whereby hardware and software are tuned for performance in tandem, as opposed to the typical story of software continuously being updated to match new hardware releases. This work has been performed as part of the Centre of Excellence in Computational Biomedicine (CompBioMed) and was possible because of CompBioMed’s wide interdisciplinary expertise. Arm and Atos were valuable partners in this work and we hope this work leads to future collaborations and can act as a template for other codesign activities.

***

About Atos
Atos is a global leader in digital transformation with 111,000 employees and annual revenue of c. € 11 billion. European number one in cybersecurity, cloud and high performance computing, the Group provides tailored end-to-end solutions for all industries in 71 countries. A pioneer in decarbonization services and products, Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea), listed on Euronext Paris and included in the CAC 40 ESG and Next 20 Paris Stock indexes.

The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

Contact:
Constance Arnoux | constance.arnoux@atos.net | +33 (0)6 44 12 16 35

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting